Abstract
Hypothalamus-pituitary-adrenal (HPA) axis, as the key moderator in energy metabolism, plays an important role in diabetes. The endogenous cannabinoid system (eCBs) involves in neuronal functions, and simultaneously cannabinoid receptors are almost expressed in all regions of the hypothalamus according to a spate of reports. However, few data investigate the changes of eCBs and HPA axis in type 2 diabetes. In this study, five diabetes mellitus rhesus monkeys, five prediabetes rhesus monkeys and five healthy rhesus monkeys were observed. In the present study, we detected cell swelling and necrosis extensively in the paraventricular nucleus (PVN) and neurohypophysis in prediabetes and overt diabetes monkeys. The adrenocorticotropic hormone in the pituitary gland, adrenocorticotropic hormone receptor, and 11β-hydroxysteroid dehydrogenase in the adrenal gland were all hyper-secreted and expressed from healthy to overt diabetes. Meanwhile, the cortisol concentration in the adrenal gland was increased along with the progress of diabetes. It could be concluded that hyperfunction of the HPA axis exists in the type 2 Diabetes pathogenesis. However, we also found a weakened expression and secretion of corticotrophin releasing hormone and glucocorticoids receptor in PVN. The expression of corticotropin releasing hormone receptor 1 in pituitary gland decreased in prediabetes monkeys, but increased in overt diabetes monkeys. The downregulation of cannabinoid receptor 1 and upregulation of monoglycerol lipase and fatty acid amide hydrolase in PVN was involved in the pathogenesis of type 2 diabetes. Collectively, we can conclude that changes in endocannabinoid hydrolase and cannabinoid receptor might indicate the effect of downregulation of eCBs. It can be assumed that hyper-function of the HPA axis from healthy to overt diabetes is due to the undermining inhibition of eCBs. However, the regulatory mechanism of eCBs targets on the HPA axis need to be further explored.
Similar content being viewed by others
References
Chan O, Chan S, Inouye K, Vranic M, Matthews SG (2001) Molecular regulation of the hypothalamo-pituitary-adrenal axis in streptozotocin-induced diabetes: effects of insulin treatment. Endocrinology 142(4):872–879
Chiodini I, Di Lembo S, Morelli V, Epaminonda P, Coletti F, Masserini B, Scillitani A, Arosio M, Adda G (2006) Hypothalamic-pituitary-adrenal activity in type 2 diabetes mellitus: role of autonomic imbalance. Metabolism 55:1135–1140
Davies SN, Pertwee RG, Riedel G (2002) Functions of cannabinoid receptors in the hippocampus. Neuropharmacology 42:993–1007
Di S, Malcher-Lopes R, Halmos KC, Tasker JG (2003) Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: a fast feedback mechanism. J Neurosci 23:4850–4857
Freund TF, Katona I, Piomelli D (2003) Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83:1017–1066
Gong L, Zeng W, Yang Z, Chen Z, Cheng A, Shen Y, Zeng L, Luo Q, Yang Y (2013) Comparison of the clinical manifestations of type 2 diabetes mellitus between rhesus monkey (Macaca mulatta lasiotis) and human being. Pancreas 42:537–542
Gray JM, Wilson CD, Lee TTY, Pittman QJ, Deussing JM, Hillard CJ, McEwen BS, Schulkin J Karatsoreos IN, Patel S, Hill MN (2016) Sustained glucocorticoid exposure recruits cortico-limbic CRH signaling to modulate endocannabinoid function. Psychoneuroendocrinology 66:151–158
Hansen BC (2012) Investigation and treatment of type 2 diabetes in nonhuman primates. Meth Mol Biol 933:177–185
Hill MN, Tasker JG (2012) Endocannabinoid signaling, glucocorticoid-mediated negative feedback, and regulation of the hypothalamic-pituitary-adrenal axis. Neuroscience 204:5–16
Hillard CJ, Beatka M, Sarvaideo J (2016) Endocannabinoid signaling and the hypothalamic-pituitary-adrenal Axis. Compr Physiol 7:1–15
Iannotti FA, Piscitelli F, Martella A, Mazzarella E, Allara M, Palmieri V, Parrella C, Capasso R, Di Marzo V (2013) Analysis of the “endocannabinoidome” in peripheral tissues of obese Zucker rats. Prostaglandins Leukot Essent Fat Acids 89:127–135
Lee TT, Gorzalka BB (2012) Timing is everything: evidence for a role of corticolimbic endocannabinoids in modulating hypothalamic-pituitary-adrenal axis activity across developmental periods. Neuroscience 204:17–30
Li C, Jones PM, Persaud SJ (2011) Role of the endocannabinoid system in food intake, energy homeostasis and regulation of the endocrine pancreas. Pharmacol Ther 129:307–320
Noguchi S, Ohno Y, Aoki N (2007) Adrenocortical insufficiency in Otsuka long-Evans Tokushima fatty rats, a type 2 diabetes mellitus model. Metabolism 56:1326–1333
Roberts CJ, Stuhr KL, Hutz MJ, Raff H, Hillard CJ (2014) Endocannabinoid signaling in hypothalamic-pituitary-adrenocortical axis recovery following stress: effects of indirect agonists and comparison of male and female mice. Pharmacol Biochem Behav 117:17–24
Rohrbasser LJ, Alsaffar H, Blair J (2018) The hypothalamus–pituitary axis. In: Belfiore A, LeRoith D (eds) Principles of endocrinology and hormone action. Springer, Cham, pp 287–321
Sharma AN, Wigham J, Veldhuis JD (2014) Corticotropic axis drive of overnight cortisol secretion is suppressed in adolescents and young adults with type 1 diabetes mellitus. Pediatr Diabetes 15:444–452
Steiner M, Marsicano G, Holsboer F, Lutz B, Wotjak CT (2006) Cannabinoid receptor 1 (CB1) signaling acts as a major regulatory mechanism of hypothalamus–pituitary–adrenal (HPA) axis mediated corticosterone secretion. Front Neuroendocrinol 27:39
Surkin PN, Gallino SL, Luce V, Correa F, Fernandez-Solari J, De Laurentiis A (2017) Pharmacological augmentation of endocannabinoid signaling reduces the neuroendocrine response to stress. Psychoneuroendocrinology 87:131–140
Trettel J, Levine ES (2003) Endocannabinoids mediate rapid retrograde signaling at interneuron right-arrow pyramidal neuron synapses of the neocortex. J Neurophysiol 89:2334–2338
Wagner JE, Kavanagh K, Ward GM, Auerbach BJ, Jr HH, Kaplan JR (2006) Old world nonhuman primate models of type 2 diabetes mellitus. ILAR J 47:259–271
Yi SS, Hwang IK, Shin JH, Choi JH, Lee CH, Kim IY, Kim YN, Won MH, Park IS, Seong JK, Yoon YS (2010) Regulatory mechanism of hypothalamo-pituitary-adrenal (HPA) axis and neuronal changes after adrenalectomy in type 2 diabetes. J Chem Neuroanat 40:130–139
Younts TJ, Castillo PE (2014) Endogenous cannabinoid signaling at inhibitory interneurons. Curr Opin Neurobiol 26:42–50
Acknowledgements
The work is supported by the National Key Scientific Instrument and Equipment Development Project of China (2013YQ49085906), the National Key Technology R&D Program of the Ministry of Science and Technology (2014BAI03B01).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Luo, Q., Chen, S., Deng, J. et al. Endocannabinoid hydrolase and cannabinoid receptor 1 are involved in the regulation of hypothalamus-pituitary-adrenal axis in type 2 diabetes. Metab Brain Dis 33, 1483–1492 (2018). https://doi.org/10.1007/s11011-018-0255-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11011-018-0255-x